PROMO!
First order? Get 10% OFF with this code: 1storder
FOXO4-DRI is a synthetic D-retro-inverso peptide derived from the FOXO4 protein sequence and studied as a molecular research tool for investigating FOXO4-related cellular signaling and protein–protein interactions.
A functional portion of the forkhead box O4 (FOXO4) transcription factor is the source of the synthetic cell-penetrating peptide FOXO4-DRI. It was created as an experimental instrument to study the relationships between FOXO4 and the tumor-suppressor protein p53 (TP53). The term "DRI" describes a D-retro-inverso configuration, where the peptide contains D-amino acids in a reversed sequence arrangement meant to change sensitivity to proteolytic breakdown while maintaining some elements of side-chain structure.
Instead of being a naturally occurring full-length FOXO4 protein, FOXO4-DRI is structurally a linear peptide. It has been studied as a method for improving peptide stability in experimental systems because of its D-retro-inverso design, which sets it apart from traditional L-amino acid peptides.
FOXO4-DRI became recognised in research following work by Baar and colleagues (2017) examining FOXO4–p53 interactions in cellular senescence models. The peptide was developed to experimentally interfere with this protein–protein interaction and has subsequently attracted interest as a molecular probe for studying senescent-cell biology, transcription-factor interactions, p53 localisation and apoptosis-associated signalling.
Laboratory investigations have employed cultured cell systems, fluorescence microscopy, protein-interaction assays and preclinical animal models to characterise FOXO4-DRI. Because its published evidence base remains predominantly preclinical, it is most appropriately described as an investigational synthetic peptide and protein–protein interaction research tool, rather than a compound with an established clinical application.
A synthetic D-retro-inverso peptide called FOXO4-DRI is made from a FOXO4 sequence that interacts with p53 through protein-protein interactions. FOXO4-DRI employs D-amino acids organized in the opposite sequence order to the corresponding parent sequence, in contrast to typical peptides that are primarily made of naturally occurring L-amino acids. The goal of this retro-inverso design is to significantly change the peptide backbone while retaining some of the original side-chain orientation.
The primary structure is linear and contains no disulfide bonds or complex post-translational modifications. Because FOXO4-DRI is relatively short compared with the full-length FOXO4 transcription factor, it does not reproduce the complete secondary or tertiary architecture of the native protein. Its conformation remains dependent on sequence, solvent environment and interaction with molecular binding partners.
FOXO4-DRI contains a combination of basic, acidic, polar and hydrophobic residues, producing an amphipathic molecular character. Ionisable side chains give the peptide a pH-dependent charge, while its physicochemical behaviour and aqueous solubility depend on concentration, buffer composition, counter-ion and formulation.
Its proteolytic stability is a very significant feature. Many proteases that typically digest L-peptides find it more difficult to recognize the peptide backbone when D-amino acids are included. As a result, compared to the comparable L-peptide, the D-retro-inverso structure has been studied as a structural strategy to increase resistance to enzyme degradation. RP-HPLC and mass spectrometry are commonly used in analytical characterization to confirm molecular identity and purity.
Current laboratory investigations have examined FOXO4-DRI primarily as a synthetic D-retro-inverso peptide designed to interfere with the protein–protein interaction between the transcription factor FOXO4 and the tumour-suppressor protein p53 (TP53). The best-characterised mechanistic work originates from preclinical cellular-senescence studies, and FOXO4-DRI does not have a conventional cell-surface receptor identified as its primary target.
FOXO4–p53 Interaction
According to published experimental research, FOXO4 interacts with p53 in senescent cells. In order to break this chemical bond, FOXO4-DRI was created as a competitive peptide. Instead of activating or inhibiting a conventional receptor, the peptide may interfere with the development of the FOXO4–p53 complex, according to cellular tests and protein-interaction assays.
p53 Localisation and Signalling
In vitro models have explored the consequences of FOXO4–p53 disruption for the intracellular localisation of p53. Baar and colleagues reported that FOXO4-DRI treatment was associated with exclusion of active p53 from the nucleus in senescent cells. This redistribution has been investigated in relation to downstream p53-dependent signalling and cell-fate regulation.
Apoptosis-Associated Pathways
Experimental investigations that have been published have investigated whether activation of apoptosis-related processes in senescent cellular models is linked to disruption of FOXO4–p53 connections. Studies have focused on caspase-dependent mechanisms and signaling linked with mitochondria. Crucially, these findings do not prove that FOXO4-DRI is a generally selective inducer of apoptosis; rather, they relate to experimental senescent-cell systems.
Cellular Entry and Proteolytic Resistance
FOXO4-DRI has also been investigated for its ability to access intracellular targets. Its D-retro-inverso configuration provides resistance to many proteases that preferentially recognise natural L-amino-acid peptide backbones, allowing the peptide to be examined in intracellular protein-interaction studies.
All things considered, FOXO4-DRI is primarily described as an experimental protein–protein interaction disruptor that targets the FOXO4–p53 axis. Preclinical research, especially the 2017 study by Baar and colleagues, continues to be the main source of evidence for the suggested mechanism; nonetheless, additional independent mechanistic examination is needed to clarify its molecular selectivity and broader intracellular connections.
This summary reflects findings reported in published preclinical and in vitro research. The original studies supporting this information are listed in the references.
The molecular connection between FOXO4 and p53 (TP53) is a key focus of FOXO4-DRI research. An experimental approach for examining the function of this transcription-factor interaction in cellular regulation has been provided by protein-interaction experiments that have examined whether FOXO4-DRI competes with endogenous FOXO4 for p53-associated binding.
FOXO4-DRI has been investigated extensively in senescent cell models, including cells driven into senescence through DNA-damage-associated or replicative mechanisms. Researchers have used these systems to examine FOXO4 localisation, p53-associated signalling and differences in cellular responses between senescent and non-senescent populations.
Changes in p53 intracellular localization after FOXO4-DRI exposure have been examined using fluorescence microscopy and molecular imaging techniques. The distribution of p53 between the nuclear and cytoplasmic compartments and its connection to FOXO4-dependent molecular interactions are investigated in these research.
Preclinical studies have examined apoptosis-associated pathways following disruption of the FOXO4–p53 interaction. Experimental techniques have included caspase assays, viability measurements and molecular markers of programmed cell death, allowing researchers to characterise downstream cellular events in senescent experimental systems.
FOXO4-DRI is also investigated more broadly as a model for peptide-mediated disruption of intracellular protein–protein interactions. Its design provides a research platform for examining whether short synthetic sequences can reproduce interaction surfaces derived from larger transcription factors and compete with endogenous protein complexes.
The unusual structural configuration of FOXO4-DRI makes retro-inverso peptide chemistry an important research area. Studies examine how reversing the sequence while substituting D-amino acids affects molecular recognition, proteolytic resistance and intracellular persistence compared with conventional L-amino-acid peptides.
FOXO4-DRI has also been investigated in preclinical animal models to examine the biological consequences of experimentally targeting FOXO4–p53 interactions in vivo. These studies complement cell-culture experiments by enabling investigation of molecular markers, tissue-level responses and senescent-cell-associated processes within more complex biological systems.
An important continuing area of investigation concerns the specificity of FOXO4-DRI. Experimental research is needed to characterise its complete binding profile, potential interactions with proteins other than p53, and differences between cellular models. This remains particularly relevant because the published FOXO4-DRI evidence base is relatively small and predominantly preclinical.
Rather than depending just on peptide purity, analytical verification of FOXO4-DRI should precisely confirm its D-retro-inverso composition. After chemical synthesis, the target peptide can be separated from shortened sequences, deletion products, and other synthesis-related impurities using reverse-phase HPLC (RP-HPLC), and chromatographic purity can be evaluated using analytical RP-HPLC.
LC-MS or high-resolution mass spectrometry can be used to confirm that the acquired molecular mass corresponds to the prescribed FOXO4-DRI sequence. However, amino acid chirality cannot be determined by conventional mass spectrometry alone since equivalent D- and L-peptides may have the same molecular mass. To confirm the D-amino-acid configuration, appropriate stereochemical controls or other methods, such as chiral amino-acid analysis following hydrolysis, are therefore required.
When additional sequence-level confirmation is required, tandem mass spectrometry (MS/MS) can provide it. A batch-specific CoA should document the specified D-retro-inverso sequence, chromatographic purity, observed molecular mass, analytical methodology, batch identification, and suitable acceptance criteria.
FOXO4-DRI should be stored at 2–8°C according to the current batch documentation. Lyophilised material should be kept tightly sealed and protected from moisture, excessive heat, and direct light.
For laboratory handling, allow refrigerated vials to equilibrate to room temperature while sealed before opening to minimise condensation. After reconstitution, store according to the requirements of the specific formulation and experimental procedure. Record the reconstitution date, storage temperature, and batch identification for laboratory traceability.
DRI stands for D-retro-inverso. It describes a peptide-design strategy in which D-amino acids are arranged in the reverse sequence order relative to the corresponding L-amino-acid peptide. This approach has been investigated as a way of retaining aspects of side-chain presentation while substantially changing the peptide backbone and its susceptibility to enzymatic degradation.
An analog created from D-amino acids in a different order than the original L-peptide is called a D-retro-inverso peptide. This structure can approximate the spatial orientation of particular side chains seen in the original peptide while producing an inverted peptide backbone. The effects of D-retro-inverso design on molecular recognition and proteolytic stability are often investigated in peptide chemistry.
FOXO4-DRI was designed from a region of the FOXO4 transcription factor involved in its interaction with p53. Rather than reproducing the complete FOXO4 protein, researchers created a shorter peptide corresponding to the relevant interaction region and converted it into a D-retro-inverso configuration for experimental investigation.
Many naturally occurring proteases have evolved to recognise peptide bonds and structural features associated with L-amino-acid peptides. Because FOXO4-DRI is composed of D-amino acids in a retro-inverso arrangement, it is less readily recognised by many of these enzymes. This provides greater proteolytic resistance than would generally be expected from the corresponding conventional L-peptide, although it does not make the molecule completely resistant to all forms of chemical degradation.
FOXO4 is a forkhead-family transcription factor, while p53 (TP53) is a transcription factor involved in cellular responses to DNA damage, stress and cell-fate regulation. Published experimental research has characterised an interaction between FOXO4 and p53 in senescent-cell models, providing the molecular basis for investigating disruption of this protein–protein interaction using FOXO4-DRI.
FOXO4-DRI was designed to compete with endogenous FOXO4 for interaction with p53, and experimental work has supported disruption of the FOXO4–p53 interaction. However, the complete binding interface, affinity and selectivity profile of FOXO4-DRI have not been characterised to the same extent as those of established receptor–ligand systems. It is therefore most accurate to describe direct p53 interaction as the intended and experimentally investigated molecular mechanism.
No dedicated cell-surface receptor has been established for FOXO4-DRI. The peptide was developed to act on an intracellular protein–protein interaction involving FOXO4 and p53 rather than through conventional receptor-mediated peptide signalling. Experimental research has therefore concentrated on intracellular localisation and protein interactions.
FOXO4-DRI was designed around the FOXO4–p53 interaction, but its complete molecular selectivity and off-target binding profile remain incompletely characterised. The original preclinical work reported differences in responses between senescent and non-senescent cellular models, but this does not establish absolute molecular or cellular specificity. Further binding, proteomic and independent mechanistic studies are required to define its broader interaction profile.
FOXO4-DRI is supplied for research and laboratory use only. It is not for human or animal consumption, administration, diagnosis, or therapeutic use. The information on this page is provided solely for technical and scientific research purposes.
